Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

BACKGROUND: A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian volunteers previously...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:PLoS One
المؤلفون الرئيسيون: Joachim, Agricola, Bauer, Asli, Joseph, Sarah, Geldmacher, Christof, Munseri, Patricia J., Aboud, Said, Missanga, Marco, Mann, Philipp, Wahren, Britta, Ferrari, Guido, Polonis, Victoria R., Robb, Merlin L., Weber, Jonathan, Tatoud, Roger, Maboko, Leonard, Hoelscher, Michael, Lyamuya, Eligius F., Biberfeld, Gunnel, Sandström, Eric, Kroidl, Arne, Bakari, Muhammad, Nilsson, Charlotta, McCormack, Sheena
التنسيق: Artigo
اللغة:Inglês
منشور في: Public Library of Science 2016
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4871571/
https://ncbi.nlm.nih.gov/pubmed/27192151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155702
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة